ABT-100: farnesyltransferase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6451154 |
| CHEMBL ID | 4586794 |
| SCHEMBL ID | 2731728 |
| MeSH ID | M0488416 |
| Synonym |
|---|
| a-409100 |
| abt-100 |
| abt100 |
| 4-[(2s)-2-(4-cyanophenyl)-2-hydroxy-2-(3-methylimidazol-4-yl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]benzonitrile |
| qg74wr2hre , |
| 450839-40-4 |
| abt 100 |
| unii-qg74wr2hre |
| SCHEMBL2731728 |
| DTXSID60196377 |
| heuvrfnvtlgkmz-sanmltnesa-n |
| CS-0077432 |
| HY-119257 |
| MS-29364 |
| CHEMBL4586794 |
| (1,1'-biphenyl)-3-carbonitrile, 6-((2s)-2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1h-imidazol-5-yl)ethoxy)-4'-(trifluoromethoxy)- |
| 6-((2s)-2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1h-imidazol-5-yl)ethoxy)-4'-(trifluoromethoxy)-1,1'-biphenyl-3-carbonitrile |
| 6-((2s)-2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1h-imidazol-5-yl)ethoxy)-4'-(trifluoromethoxy)(1,1'-biphenyl)-3-carbonitrile |
| AKOS040732365 |
ABT-100 is a highly selective, potent and orally bioavailable FTI. It shows 70% to 80% oral bioavailability in mice.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a Wistar to Lewis rat heterotopic cardiac transplant model, ABT-100 was orally dosed alone or with a subtherapeutic course of cyclosporine (CsA)." | ( Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. Imagawa, DK; Ji, P; Kusumoto, J; Kwok, J; Lee, M; Naasz, E; Ng, SC; Si, MS, 2005) | 0.84 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Histamine H1 receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.5110 | 10.0000 | AID1794426 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Ephrin type-A receptor 1 | Homo sapiens (human) | Kd | 10.0000 | 0.0041 | 1.8000 | 9.8000 | AID1794066 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Kd | 10.0000 | 0.0025 | 1.6783 | 7.7000 | AID1794010 |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | Kd | 10.0000 | 0.0035 | 1.9863 | 8.9000 | AID1793985 |
| Serine/threonine-protein kinase Nek7 | Homo sapiens (human) | Kd | 10.0000 | 0.0030 | 3.6719 | 8.7000 | AID1794229 |
| Aurora kinase B | Homo sapiens (human) | Kd | 10.0000 | 0.0020 | 1.0614 | 22.8520 | AID1793972 |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | 0.0073 | 1.3739 | 5.0000 | AID1794125 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||